These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 36503556)
21. Effect of adding androgen deprivation therapy to permanent iodine-125 implantation with or without external beam radiation therapy on the outcomes in patients with intermediate-risk prostate cancer: A propensity score-matched analysis. Sutani S; Yorozu A; Toya K; Shiraishi Y; Nishiyama T; Yagi Y; Nakamura K; Saito S Brachytherapy; 2021; 20(1):10-18. PubMed ID: 33069598 [TBL] [Abstract][Full Text] [Related]
22. Combining prostate-specific antigen nadir and time to nadir allows for early identification of patients at highest risk for development of metastasis and death following salvage radiation therapy. Jackson WC; Johnson SB; Foster B; Foster C; Li D; Song Y; Vainshtein J; Zhou J; Hamstra DA; Feng FY Pract Radiat Oncol; 2014; 4(2):99-107. PubMed ID: 24890350 [TBL] [Abstract][Full Text] [Related]
23. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Choueiri TK; Xie W; D'Amico AV; Ross RW; Hu JC; Pomerantz M; Regan MM; Taplin ME; Kantoff PW; Sartor O; Oh WK Cancer; 2009 Mar; 115(5):981-7. PubMed ID: 19152438 [TBL] [Abstract][Full Text] [Related]
24. PSA provocation by bipolar androgen therapy may predict duration of response to first-line androgen deprivation: Updated results from the BATMAN study. Denmeade S; Lim SJ; Isaaccson Velho P; Wang H Prostate; 2022 Dec; 82(16):1529-1536. PubMed ID: 35938545 [TBL] [Abstract][Full Text] [Related]
25. Favorable prognosis of patients who received adjuvant androgen deprivation therapy after radiotherapy achieving undetectable levels of prostate-specific antigen in high- or very high-risk prostate cancer. Jeong JU; Nam TK; Song JY; Yoon MS; Ahn SJ; Chung WK; Cho IJ; Kim YH; Cho SH; Jung SI; Kang TW; Kwon DD PLoS One; 2021; 16(3):e0248461. PubMed ID: 33711055 [TBL] [Abstract][Full Text] [Related]
26. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy. Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728 [TBL] [Abstract][Full Text] [Related]
27. Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era? Castle KO; Hoffman KE; Levy LB; Lee AK; Choi S; Nguyen QN; Frank SJ; Pugh TJ; McGuire SE; Kuban DA Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):693-9. PubMed ID: 22836052 [TBL] [Abstract][Full Text] [Related]
28. Impact of neoadjuvant prostate-specific antigen kinetics on biochemical failure and prostate cancer mortality: results from a prospective patient database. Foo M; Lavieri M; Pickles T Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):385-92. PubMed ID: 22652112 [TBL] [Abstract][Full Text] [Related]
29. Prostate-Specific Antigen Response to Androgen Deprivation Therapy in the Neoadjuvant Setting for High-Risk Prostate Adenocarcinoma (PIRANHA): Pooled Analysis of Two Randomized Clinical Trials. Nikitas J; Ong WL; Carrier N; Romero T; Millar J; Steinberg ML; Rettig MB; Boutros PC; Reiter R; Nickols NG; Valle L; McGuire SE; Spratt DE; Souhami L; Roy S; Martin JM; Joseph D; Nabid A; Kishan AU Int J Radiat Oncol Biol Phys; 2024 Jul; 119(3):826-831. PubMed ID: 38151191 [TBL] [Abstract][Full Text] [Related]
30. Higher than standard radiation doses (> or =72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer. Kupelian PA; Mohan DS; Lyons J; Klein EA; Reddy CA Int J Radiat Oncol Biol Phys; 2000 Feb; 46(3):567-74. PubMed ID: 10701735 [TBL] [Abstract][Full Text] [Related]
31. Early biochemical predictors of survival in intermediate and high-risk prostate cancer treated with radiation and androgen deprivation therapy. Patel MA; Kollmeier M; McBride S; Gorovets D; Varghese M; Chan L; Knezevic A; Zhang Z; Zelefsky MJ Radiother Oncol; 2019 Nov; 140():34-40. PubMed ID: 31177042 [TBL] [Abstract][Full Text] [Related]
32. Long-term follow-up comparing salvage radiation therapy and androgen-deprivation therapy for biochemical recurrence after radical prostatectomy. Matsumoto K; Niwa N; Hagiwara M; Kosaka T; Takeda T; Yasumizu Y; Tanaka N; Morita S; Mizuno R; Shinojima T; Hara S; Asanuma H; Oya M Int J Clin Oncol; 2021 Apr; 26(4):744-752. PubMed ID: 33387085 [TBL] [Abstract][Full Text] [Related]
33. The role of androgen deprivation therapy on biochemical failure and distant metastasis in intermediate-risk prostate cancer: effects of radiation dose escalation. Ludwig MS; Kuban DA; Strom SS; Du XL; Lopez DS; Yamal JM BMC Cancer; 2015 Mar; 15():190. PubMed ID: 25885406 [TBL] [Abstract][Full Text] [Related]
34. Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation. Kroeze SGC; Henkenberens C; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Christiansen H; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M Eur Urol Focus; 2021 Mar; 7(2):309-316. PubMed ID: 31495759 [TBL] [Abstract][Full Text] [Related]
35. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy]. Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284 [TBL] [Abstract][Full Text] [Related]
36. Different outcomes among favourable and unfavourable intermediate-risk prostate cancer patients treated with hypofractionated radiotherapy and androgen deprivation therapy. Bracci S; Osti MF; Agolli L; Bertaccini L; De Sanctis V; Valeriani M Radiat Oncol; 2016 Jun; 11():78. PubMed ID: 27276878 [TBL] [Abstract][Full Text] [Related]
37. Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial. Alexander A; Crook J; Jones S; Malone S; Bowen J; Truong P; Pai H; Ludgate C Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):23-30. PubMed ID: 19395187 [TBL] [Abstract][Full Text] [Related]